Back to today’s briefing

Story perspectives

New Enzyme Therapy Promises Safer Gene Treatment for Duchenne

8/7/2025

28 6

Summary

Story summary

Hansa Biopharma's groundbreaking enzyme therapy, imlifidase, is making waves by potentially minimizing immune responses to Sarepta’s gene therapy, Elevidys, for Duchenne muscular dystrophy. Encouraging results from three patients revealed successful gene delivery without harmful side effects. Hansa is eager to delve deeper into imlifidase's advantages, addressing fears of severe immune reactions tied to Elevidys.

1 of 1

Story summary

Hansa Biopharma's groundbreaking enzyme therapy, imlifidase, is making waves by potentially minimizing immune responses to Sarepta’s gene therapy, Elevidys, for Duchenne muscular dystrophy. Encouraging results from three patients revealed successful gene delivery without harmful side effects. Hansa is eager to delve deeper into imlifidase's advantages, addressing fears of severe immune reactions tied to Elevidys.